AUTHORS
Alexander Xiao, MD, MBA, Yi Lin Jr, MD, PhD2, Tyler Sandahl, Pharm.D., R.Ph., BCOP3, Jonathan R Day, PharmD, MD4, Nadine Abdallah I, MD5, Sikander Ailawadhi, MD6, P. Leif Bergsagel, MD7, Moritz Binder, MD, MPH8, Saurabh Chhabra, MD, MBBS9, Joselle M Cook, M.D.10, Andre De Menezes Silva Corraes, MD11, Angela Dispenzieri, MD12, Morie Gertz13, Wilson Gonsalves, MD14, Taxiarchis Kourelis, MD15, Nelson Leung, MD16, Ricardo Daniel Parrondo, MD17, Christoph Schaefers, MD18, Rahma Warsame, MD19, J Erin Wiedmeier-Nutor, MD,MPH20, Udit Yadav, MBBS21, S. Vincent Rajkumar, MD22, Rafael Fonseca, MD23, Prashant Kapoor, MD24, Shaji Kumar, MD25, Saurabh Zanwar, MBBS, MD26
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Jacksonville, Florida, United States
7 Mayo Clinic, Phoenix, Arizona, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Phoenix, Arizona, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Jacksonville, Florida, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Phoenix, Arizona, United States
21 Mayo Clinic, Phoenix, Arizona, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Phoenix, Arizona, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background: Bispecific T-cell Engagers (TCE) are effective in relapsed/refractory multiple myeloma (MM) but carry significant infectious risks. We evaluated adherence to infection prophylaxis and associations between immune parameters, intravenous immunoglobulin (IVIg) timing, infection, and survival.
Methods: This single center review included 111 patients with relapsed/refractory MM totaling 117 initiations of teclistamab (Tec) or talquetamab (Tal) between December 2022 and March 2026. IVIg was classified as administered “early” (given 28 days before or after TCE initiation), “late” (given >28 days), or “none”. Overall survival (OS) was calculated from first step-up dose to death or last follow-up. Severe infection was defined as requiring hospitalization or TCE discontinuation. Impact of a ‘templated note’ with a standardized infection prophylaxis prompt was evaluated.
Results: Of 117 TCE initiations, 92 involved Tec and 25 Tal; 6 patients received both. Median age was 69 years (IQR 64–74), 54% were female, and median prior lines of therapy was 6 (IQR 4–7). Any, severe, and recurrent infection occurred in 59 (50%), 22 (19%) and 11 (9%) episodes respectively. Among 74 infections, 39 were bacterial, 21 viral, 2 fungal, 7 mixed and 5 undetermined; pneumonia was most common (38%). Rates of any and severe infection were comparable between Tec and Tal (49% vs 56%, p=0.65; 22% vs 8%, p=0.15 respectively).
Presence of IgG nadir <400 mg/dL had higher rates of any (68% vs 37%; OR 3.5, p=0.003) and severe infections (25% vs 12%; OR 2.59, p=0.13). Median IgG nadir was lower with any (303 vs 450 mg/dL, p=0.005) and severe infection (190 vs 380 mg/dL, p=0.02). Each additional prior line of therapy increased infection risk, OR 1.17, p=0.01.
IVIg was given early in 47 (40%), late in 35 (30%), and not given in 35 (30%) TCE initiations. Median IgG nadirs were 380, 225, and 1,330 mg/dL for the early, late and no IVIg groups, with median time on TCE of 5.2, 11.7 and 1.1 months, respectively. Any infection occurred in 18 (38%) early, 29 (83%) late and 12 (34%) no IVIg cohorts (p=0.001); severe infection occurred in 4 (9%), 13 (37%) and 5 (14%) respectively, p=0.005. Odds ratios for any and severe infections between early and late IVIg cohorts were 0.13 (p<0.01) and 0.16 (p<0.01), respectively.
Rate of infections was 5.6 per 100 months on TCE overall and 4.2, 5.2 and 14 per 100 months for the early, late and no IVIg groups respectively. After adjusting for TCE exposure >3 months and baseline IgG, early vs late IVIg was associated with lower odds of any (OR 0.12, p=0.001) and severe infection (OR 0.14, p=0.01).
Median OS for the cohort was 23.7 (95% CI 14.7-31.6) months; median OS was lower with early vs late IVIg (25 vs 30.9 months, p=0.04). Rates of high-risk cytogenetics, penta-class refractoriness, prior BCMA therapy and extramedullary disease were similar between early and late IVIg groups. Of 59 deaths, infections were the second most common cause (n=11, 19%); 37 (63%) were due to MM progression. Infectious cause of death was comparable by IVIg group; 6 (26%) early, 2 (20%) late and 3 (12%) no IVIg, p=0.4.
PJP prophylaxis was prescribed in 113 (97%) episodes and 64 (55%) remained on first-line trimethoprim-sulfamethoxazole (TMP-SMX). Common reasons for discontinuation were renal injury (25%), pancytopenia (19%), allergy (11%) and adherence or prescription issues (11%). A templated prophylaxis checklist was utilized in 98 (84%) episodes and associated with greater documented PJP prophylaxis prescription [97 (99%) vs 16 (84%), p=0.01] and TMP-SMX compliance [59 (60%) vs 5 (26%), p=0.01]. No PJP infections were recorded. Antiviral prophylaxis was prescribed for all patients. CD4 counts were checked in 29 (25%) episodes with 79% <200/µL. HBV screening was performed before 26% of initiations, with one reactivation. CMV viremia occurred in 19 (16%) initiations, all asymptomatic.
Conclusion: Infections were common during TCE therapy, accounting for significant mortality. Severe hypogammaglobulinemia (<400 mg/dL) was associated with higher infection risk, and early IVIg administration (<28 days from TCE start) was associated with fewer and less severe infections than delayed administration. Testing for CD4 counts, CMV viremia and HBV were relatively low and gaps were present in TMP-SMX compliance. These findings highlight opportunities to improve infection prevention practices in patients receiving TCEs and support early initiation of IVIg.
DISCLOSURES
Alexander Xiao, MD, MBA: No relevant conflicts of interest to declare.